about
Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF TrialsEffect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failureThe Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristicsAbsence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction studyLeft ventricular assessment in myocardial infarction: the VALIANT registryEvaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance AggregoPlatelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel?Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivityPlatelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet SubstudyAntithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyDoes heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity?A reappraisal of loop diuretic choice in heart failure patientsEffects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trialTorsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairmentCombinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphismsImpaired resting myocardial annular velocities are independently associated with mental stress-induced ischemia in coronary heart disease.Clinical implications of chronic heart failure phenotypes defined by cluster analysis.Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials).Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study.Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function.Developing therapies for heart failure with preserved ejection fraction: current state and future directionsPrognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory SupportAdmission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trialMyocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of ExercEfficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trialAssociations between seattle heart failure model scores and medical resource use and costs: findings from HF-ACTION.The past, present and future of renin-angiotensin aldosterone system inhibitionPhobic anxiety and increased risk of mortality in coronary heart disease.A review of dyspnea in acute heart failure syndromes.Heart failure in elderly patients: distinctive features and unresolved issues.Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapySoluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
P50
Q26786687-64573F52-87EA-4D6E-834A-063848057EA4Q28167773-D65BDDCC-9F6C-4206-840C-5906DC6BF628Q28168358-C9D9B024-CD23-4F71-AF3F-35056EAAC234Q28171113-DAC5FF48-BE4E-46E4-85F5-9ED8B51A2841Q28192571-737560DE-7058-4AB4-AF5E-01BE80808E2CQ28193247-E5E58B1B-7DAC-482E-B222-22268E7FFBB8Q28193696-A317939F-43F4-482B-BE21-2F3492FE93ECQ28195513-D6AA9948-D00C-4CE4-A20D-5C0C14D5BC42Q28196405-FAC56362-0097-45A5-A04C-10D21CB7431EQ28199056-DA758CC6-C0A8-45E9-903C-B3AFD135572CQ28213459-27F99761-99ED-46BC-853B-503513325BF2Q28218798-9594C8B8-4668-4978-8522-EAFBA4E46617Q28258044-1D7DDC1A-560B-45A6-AAC7-270D6F36A0AFQ28258946-E79400BE-41CC-4800-9399-B18EED96C215Q28271500-BC45C9B5-BB91-46C8-901D-323365060B8CQ28297684-7E13A831-3EA5-4801-B614-5093A0AB1DD7Q28484344-D2B7E67B-57BB-4E8E-AB60-E8B7326A392AQ30415445-E2A9DBFF-09B2-4D29-85BE-7476FBD39EC4Q30604593-8C46E853-05CF-4ADB-A7D9-D2523127832EQ30724401-ADD8B6E7-127B-41F5-A5C1-87FCFB63FD2DQ31043636-B4D6BA8F-5BF5-48E5-B230-DC4C0C5CCC25Q31141404-BD3CC5F6-37B0-4DDE-A937-1A4C5A1C8725Q33196686-2CD1AC00-C5F6-42EF-811E-34311B8076F3Q33506869-2B0BCA1E-CEA5-4921-844A-CF8AC63E628BQ33558822-34F05134-6ABD-4235-BD92-77622196D09CQ33639223-84E4FC26-1382-4495-A301-EA3B2597540FQ33677357-94E8CF62-A468-4FEA-9E64-5A8D82AE173EQ33956698-4D56D92D-2423-4A6E-83F5-CB1D46C9B43CQ34001004-91F0B1A4-039B-49E9-A5AF-EDC764BC18EAQ34013610-398ED2F4-A46B-4389-A784-9B3C8EB50387Q34046673-2CF944E1-144D-4A20-AF5F-7B98A6EACEB8Q34066472-F9AB5C92-E343-485E-AAA8-0C908966962FQ34094354-DFB38982-37D2-4351-84CC-BB07A769CBABQ34126266-E42C0F3D-0AC1-4793-A7E6-6070BE242EF3Q34130157-44370640-DB48-474B-A8E3-C196A211AA8FQ34248538-2802D7FD-7246-4F0D-B838-88455476F713Q34248663-B31A79B9-C8D1-486F-8DB1-5D6FA7AC78DFQ34249097-D7D3FF10-D4D2-4FCD-87AC-85CA7174DD49Q34300880-06391BF8-033C-4744-9B14-BA1292848E13Q34324771-146A24F6-3D82-42E1-A16A-D40C21A4239F
P50
name
Christopher M O'Connor
@ast
Christopher M O'Connor
@en
Christopher M O'Connor
@nl
type
label
Christopher M O'Connor
@ast
Christopher M O'Connor
@en
Christopher M O'Connor
@nl
prefLabel
Christopher M O'Connor
@ast
Christopher M O'Connor
@en
Christopher M O'Connor
@nl
P214
P101
P108
P21
P214
P31
P734
P7859
lccn-nr2005022967